Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2016

01-02-2016 | Leading Article

New Targets in the Drug Treatment of Heart Failure

Authors: James A. Iwaz, Elizabeth Lee, Hermineh Aramin, Danilo Romero, Navaid Iqbal, Matt Kawahara, Fatima Khusro, Brian Knight, Minal V. Patel, Sumita Sharma, Alan S. Maisel

Published in: Drugs | Issue 2/2016

Login to get access

Abstract

Heart failure is a complex syndrome that has been a major contributor to readmissions into hospitals in the USA. Currently, a large number of medications are being used to treat the symptoms of the disease—digoxin, diuretics, renin-angiotensin-aldosterone system inhibitors, β-blockers, and vasodilators. There is no doubt that the given pharmaceutical therapy has been effective in lowering hospital readmission rates and prolonging life in individual chronic heart failure patients. Despite this, admission rates following heart failure hospitalization remain high, resulting in a substantial financial strain on healthcare institutions. Clearly, there is much room for improvement in heart failure therapy and management in reducing readmission rates. In this review, we address the unmet needs in the current drug treatment of chronic heart failure and describe novel drug targets that are currently under investigation.
Literature
1.
Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257–63.PubMedCrossRef
2.
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRef
3.
Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933–89.PubMedCrossRef
4.
Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1–90.PubMedCrossRef
5.
Lloyd-Jones D, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–215.PubMedCrossRef
6.
Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the US, 1979 to 2004. J Am Coll Cardiol. 2008;52:428–34.PubMedCrossRef
7.
8.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.PubMedCrossRef
9.
López-Sendón J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE inhibitors of the European Society of Cardiology. Eur Heart J. 2004;25:1454–70.PubMedCrossRef
10.
López-Sendón J, et al. Expert consensus document on β-adrenergic receptor blockers. Task Force on beta-blockers of the European Society of Cardiology. Eur Heart J. 2004;25:1341–62.PubMedCrossRef
11.
Solomon SD, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic dysfunction: a randomized trial. Lancet. 2007;369 (9579): 2079–87 (→ ARB in HFpEF).
12.
Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2009;53(2):184–92.PubMedPubMedCentralCrossRef
13.
Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.PubMedCrossRef
14.
Kazuhiro Y, et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J of Heart Failure. 2014;15(1):110–8.
15.
Massie BM, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Eng J Med. 208;359:2456–67.
16.
Paulus WJ, Ballegoij J. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010;55(6):526–37.PubMedCrossRef
17.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Eng J Med. 1997;336:525–33.CrossRef
18.
WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327. doi:10.​1161/​CIR.​0b013e31829e8776​.CrossRef
19.
Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616–35.PubMedCrossRef
20.
Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999;59(16):4148–54.PubMed
21.
van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6(2):219–26. doi:10.​1161/​CIRCHEARTFAILURE​.​112.​000129.PubMedCrossRef
22.
Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323–8. doi:10.​1007/​s00392-010-0125-y.PubMedPubMedCentralCrossRef
23.
Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012;164(6):878–83. doi:10.​1016/​j.​ahj.​2012.​08.​021.PubMedCrossRef
24.
van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–24.PubMedCrossRef
25.
Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Silljé HH, de Boer RA. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107–17. doi:10.​1161/​CIRCHEARTFAILURE​.​112.​971168.PubMedCrossRef
26.
Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–8.PubMedCrossRef
27.
Liu YH, D’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, André S, Gabius HJ, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296(2):H404–12. doi:10.​1152/​ajpheart.​00747.​2008.PubMedPubMedCentralCrossRef
28.
Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33(1):67–75. doi:10.​1161/​ATVBAHA.​112.​300569.PubMedCrossRef
29.
Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens. 2004;22(3):593–603.PubMedCrossRef
30.
Ahmed A, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27(12):1431–9.PubMedPubMedCentralCrossRef
31.
Lax A, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015;3(1):50–8.PubMedCrossRef
32.
Weir R, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. 2013;6:492–8.PubMedCrossRef
33.
Fiuzat M, et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 2014;20(1):38–44.PubMedPubMedCentralCrossRef
34.
Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocites and myocardial infarction. Circulation. 2002;106:2961–6.PubMedPubMedCentralCrossRef
35.
Ronco C, Costanzo MR, Bellomo R, Maisel A. Fluid overload: diagnosis and management. Contrib Nephrol. 2010;164:209–16.CrossRef
36.
Sanada S, Hakuno D, Higgins LJ, et al. IL—33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.PubMedPubMedCentralCrossRef
37.
Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin-1 receptor family member T1/ST2 in T Helper cell type-2 mediated lung mucosal immune responses. J Exp Med. 1999;190:895–902.PubMedPubMedCentralCrossRef
38.
Schmitz J, Owyang A, Oldham E, et al. IL—33, an interleukin—1 like cytokine that signals via the IL—1 receptor related protein ST2 and induces T helper type-2 associated cytokines. Immunity. 2005;23:479–90.PubMedCrossRef
39.
Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7(3):418–26.PubMedCrossRef
40.
Gaggin HK, Szymonikfa J, Bharadwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2(1):65–72.PubMedCrossRef
41.
Lassus J, Gayat E, Mueller C et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the multinational observational cohort on acute heart failure (MOCA) study. Int J Cardiol. 2013;163(3):2186–94.CrossRef
42.
Mueller T, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54:752–6.PubMedCrossRef
43.
Jougasaki M, et al. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997;273(4 Pt 2):R1392–9.PubMed
44.
Hirayama N, et al. Molecular forms of circulating adrenomedullin in patients with congestive heart failure. J Endocrinol. 1999;160:297–303.PubMedCrossRef
45.
Daggubati S, et al. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res. 1997;36:246–55.PubMedCrossRef
46.
Jougasaki M, Grantham JA, Redfield MM, Burnett JC Jr. Regulation of cardiac adrenomedullin in heart failure. Peptides. 2001;22:1841–50.PubMedCrossRef
47.
Meeran K, O’Shea D, Upton PD, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab. 1997;82:95–100.PubMed
48.
Peacock WF, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011;18:947–58.PubMedCrossRef
49.
Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):206276.CrossRef
50.
Xue Y, Taub P, Iqbal N, Fard A, Clopton P, Maisel A. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure. Eur J Heart Fail. 2013;15(12):1343–9.PubMedCrossRef
51.
Von Haehling S, Filipatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12:484–91.CrossRef
52.
Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J. 2005;26(6):538–43.PubMedCrossRef
53.
Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J Pharmacol Sci. 2014;124(1):1–6.PubMedCrossRef
54.
Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290(2):F273–8.
55.
Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47(8):1615–21.PubMedCrossRef
56.
Lanfear DE, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013;6:47–52.PubMedPubMedCentralCrossRef
57.
Freixa X, Heras M, Ortiz JT, Argiro S, Guasch E, Doltra A, Jimenez M, Betriu A, Masotti M. Usefulness of endothelin-1 assessment in acutemyocardial infarction. Rev Esp Cardiol. 2011;64:105–10.PubMedCrossRef
58.
Jain D, Schafer U, Dendorfer A, Kurz T, Lindemann C, Tolg R, Hartmann F, Katus HA, Richardt G. Neurohumoral activation in percutaneous coronary interventions: apropos of ten vasoactive substances during and immediately following coronary rotastenting. Indian Heart J. 2001;53:301–7.PubMed
59.
Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38–43.PubMedCrossRef
60.
Mayyas F, Al-Jarrah M, Ibrahim K, Mfady D, Van Wagoner DR. The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization. Cardiovasc Pathol. 2015;24(1):19–25.PubMedCrossRef
61.
Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18(1):38–43.PubMedCrossRef
62.
Stewart DJ, Kubac G, Costello KB, Cernacek P. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. J Am Coll Cardiol. 1991;18(1):38–43.PubMedCrossRef
63.
Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rational and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEeart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13:107–14. doi:10.​1093/​eurjhfq212.PubMedCrossRef
64.
65.
66.
Shehata M, Youssef F, Pater A. Aliskiren: is combination therapy with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBS) still a possibility? Int J Cardiovasc Res. 2012;1:2. doi:10.​4172/​2324-8602.​1000e106.CrossRef
67.
68.
69.
McMurray JJV, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trail (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062–73. doi:10.​1093/​eurjhft052.PubMedPubMedCentralCrossRef
70.
Sulfi S, Timmis AD. Ivabradine—the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60(2):222–8.PubMedPubMedCentralCrossRef
71.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85. doi:10.​1016/​S0140-6736(10)61198-1.PubMedCrossRef
72.
73.
Fox K, Ford I, Steg PG, Tendera M. Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–16. doi:10.​1016/​S0140-6736(08)61170-8.PubMedCrossRef
74.
Scicchitano P, Cortese F, Ricci G, Carbonara S, Moncelli M, Iacoviello M, Cecere A, Gesualdo M, Zito A, Caldarola P, Scrutinio D, Lagioia R, Riccioni G, Ciccone MM. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Des Devel Ther. 2014;3(8):689–700. doi:10.​2147/​DDDT.​S60591.
75.
Amano M, Nakayama M, Kailbuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010;67(9):545–54. doi:10.​1002/​cm.​20472.
76.
77.
Vahebi S, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ. Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res. 2005;96:740–7.PubMedCrossRef
78.
Mori K, Amano M, Takefuji M, Kato K, Morita Y, Nishioka T, Matsuura Y, Murohara T, Kaibuchi K. Rho-Kinase contributes to sustained RhoA activation through phosphorylation of p190A RhoGAP. J Biol Chem. 2009;284(8):5067–76. doi:10.​1074/​jbc.​M806853200 (Epub 2008 Dec 22).PubMedCrossRef
79.
Bulhak A, Roy J, Hedin U, Sjoquist PO, Pernow J. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Am J Physiol Heart Circ Physiol. 2007;292(6):H3158–63 (Epub 2007 Feb 23).PubMedCrossRef
80.
Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–4.PubMedCrossRef
81.
Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem. 2001;276:341–7.PubMedCrossRef
82.
Torsoni AS, Fonseca PM, Crosara-Alberto DP, Franchini KG. Early activation of p160ROCK by pressure overload in rat heart. Am J Physiol Cell Physiol. 2003;284:C1411–9.PubMedCrossRef
83.
Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H. Fasudil, a who kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170(2):341–51. doi:10.​1111/​bph.​12277.PubMedPubMedCentralCrossRef
84.
Ho TJ, Huang CC, Huang CY, Lin WT. Fasudil, a rho-kinase inhibitor, protects against excessive endurance exercise training induced cardiac hypertrophy, apoptosis, and fibrosis in rats. Eur J Appl Physiol. 2012;112(8):2943–55. doi:10.​1007/​s00421-011-2270-z (Epub 2011 Dec 9).PubMedCrossRef
85.
Neverova N, Teerlink JR. Serelaxin : a potential new drug for the treatment of acute heart failure. Expert Opin Investig Drugs. 2014;23(7):1017–26.PubMedCrossRef
86.
Chan LJ, Hossain MA, Samuel CS, et al. The relaxin peptide family—structure, function and clinical applications. Protein Pept Lett. 2011;18(3):220–9.PubMedCrossRef
87.
Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15(3):182–90.PubMedCrossRef
88.
Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebocontrolled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373(9673):1429–39.PubMedCrossRef
89.
Varr BC, Maurer MS. Emerging role of serelaxin in the therapeutic armamentarium for heart failure. Curr Atheroscler Rep. 2014;16(10):447.PubMedCrossRef
90.
Green SJ, et al. The cGMP Signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc. 2013;2(6):e000536.
91.
Heerebeek L, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830–9.PubMedCrossRef
92.
93.
94.
95.
Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48:1438–47.PubMedCrossRef
96.
Jabbour A, Hayward CS, Keogh AM, et al. parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13:83–92.PubMedCrossRef
97.
Gao R, Zhang J, Cheng L, et al. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebocontrolled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55:1907–14.PubMedCrossRef
98.
99.
100.
101.
Bround MJ, Wambolt R, Luciani DS, Kulpa JE, Rodrigues B, Brownsey RW, Allard MF, Johnson JD. Cardiomyocyte ATP production, metabolic flexibility, and survival require calcium flux through cardiac ryanodine receptors in vivo. J Biol Chem. 2013;288(26):18975–86. doi:10.​1074/​jbc.​M112.​427062 (PMID 23678000).PubMedPubMedCentralCrossRef
102.
Dulhunty AF, Pouliquin P. What we don’t know about the structure of ryanodine receptor calcium release channels. Clin Exp Pharmacol Physiol. 2003;30:713–23.PubMedCrossRef
103.
Wehrens XH, Marks AR. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem Sci. 2003;28:671–8.PubMedCrossRef
104.
Cheng Y, Zhan Q, Zhao J, Xiao J. Stabilizing ryanodine receptor type 2: a novel strategy for the treatment of atrial fibrillation. Med Sci Monit. 2010;16(7):HY23–6.
105.
Sacherer M, Sedej S, Wakula P, Wallner M, Vos MA, Kockskamper J, Stiegler P, Sereinigg M, von Lewinski D, Antoons G, Pieske BM, Heinzel FR. JTV519 (K201) reduces sarcoplasmic reticulum Ca2+ leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol. 2012;167(3):493–504. doi:10.​1111/​j.​1476-5381.​2012.​01995.​x.PubMedPubMedCentralCrossRef
106.
Xander HT, Wehrens SE, Lehnart SR, Reiken SD, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Sci J. 2004;304(5668):292–6.CrossRef
107.
Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of a pipeline? Nat Rev Drug Discov. 2007;6(2):127–39.PubMedCrossRef
108.
Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT(Val- sartan Heart Failure Trial). J Am Coll Cardiol. 2008;52:997–1003.PubMedCrossRef
109.
Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422–30.PubMedCrossRef
110.
111.
112.
Metadata
Title
New Targets in the Drug Treatment of Heart Failure
Authors
James A. Iwaz
Elizabeth Lee
Hermineh Aramin
Danilo Romero
Navaid Iqbal
Matt Kawahara
Fatima Khusro
Brian Knight
Minal V. Patel
Sumita Sharma
Alan S. Maisel
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0498-3

Other articles of this Issue 2/2016

Drugs 2/2016 Go to the issue

Therapy in Practice

Diagnosis and Management of Systemic Sclerosis: A Practical Approach

AdisInsight Report

Daratumumab: First Global Approval

Adis Drug Evaluation

Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections

Leading Article

Therapies to Preserve β-Cell Function in Type 1 Diabetes

AdisInsight Report

Necitumumab: First Global Approval

AdisInsight Report

Osimertinib: First Global Approval